An observational study in Lupus Erythematosus, Systemic, sponsored by AstraZeneca. Active, not recruiting at 47 sites in Japan. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Lupus Erythematosus, Systemic by AstraZeneca — 19 open to participants now, 25 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · AstraZeneca.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, this one is the 3rd largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2021, is one of 19 observational ones, reaches primary completion later than 4 of the 24 other live ones, and was the 18th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →19 of the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Australia, Belgium, Chile and 7 more countries
Ages 5–17
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
AstraZeneca · Sites in China
Ages 18–70
AstraZeneca · Sites in United States
Ages 18–130 · Women only
AstraZeneca · Sites in United States, Canada, France and 6 more countries
Ages 18–70
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,620 is above the median of 151 across 281 observational studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 109 across the 26 interventional studies, 500 across the 19 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
5 of the studies in Lupus Erythematosus, Systemic by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT06530849Gracell Biotechnologies (Shanghai) Co., Ltd.A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | 2027-02-01 |
| NCT05141201AstraZenecaSAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS) | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT06594068AstraZenecaProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Lupus Erythematosus, Systemic by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus in the real-world post-marketing setting.
The objective of the Specific Use Result Study is to collect information on and evaluate the long-term safety and effectiveness of Anifrolumab in patients with systemic lupus erythematosus insufficiently responding to currently available treatment in the real-world post-marketing setting.
This investigation will be conducted to support the application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.
patients with systemic lupus erythematosus insufficiently responding to currently available treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
patients with systemic lupus erythematosus insufficiently responding to currently available treatment -
Exclusion Criteria:
None
-
Incidence of ADRs
Incidence of ADRs related to Anifrolimab. Safety specification: Herpes zoster, serious infections, anaphylaxis, malignancy and reactivation of hepatitis B virus
Time frame: from the baseline to 52 weeks
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluatedas per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes,indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Mar 2027, 63 months after the start.
Of 112 observational studies under Lupus Erythematosus, Systemic, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 126. This study's planned 63 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →